Fig. 2
From: Therapeutic targeting of PFKFB3 and PFKFB4 in multiple myeloma cells under hypoxic conditions
Co-treatment with carfilzomib and PFK158 or 5MPN induces cytotoxicity in myeloma cells under hypoxia. A KMS-11/BTZ cells were treated with carfilzomib and/or PFK158 or 5MPN for 72 h. Cell growth was evaluated using Cell Counting Kit-8. *p < 0.05 vs. carfilzomib or PFK158- or 5MPN-treated cells. B, C KMS-11/BTZ cells were treated with carfilzomib and/or PFK158 or 5MPN for 48 h. Caspase 3/7 activity was determined using the Caspase-Glo® 3/7 Assay System. *p < 0.05 vs. carfilzomib-treated cells. D, E The gene expression profile of BCL2L10 and the correlation between BCL2L10 and PFKFB3 or PFKFB4 expressions in the myeloma samples were analyzed using GEO data (GSE80140) **p < 0.01 vs. normoxia. F U266 cells were cultured under hypoxia for 24 h and incubated with the indicated concentrations of carfilzomib and/or PFK158 or 5MPN. Total extracts were examined by immunoblot analysis using antibodies against NF-κB p65, BCL-2, BCL-XL, BCL2L10, and β-actin